Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-04
2007-09-04
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S309700
Reexamination Certificate
active
10643699
ABSTRACT:
The subject invention provides useful and novel calcium channel blockers based upon mibefradil. The subject invention also provides methods for synthesizing the compounds of the invention. The invention also provides methods for the control or prevention of hypertension, angina pectoris, ischemia, arrhythmias, and cardiac insufficiency in a patient by administering a compound, or composition, of the invention to an individual in need of such treatment.
REFERENCES:
patent: 4808605 (1989-02-01), Branca et al.
patent: 5620975 (1997-04-01), Clozel et al.
patent: 0 524 512 (1993-01-01), None
patent: 11035483 (1999-02-01), None
Bursztyn, M., et at., “Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: Favorable hemodynamics and pharmacokinetics”,American Heart Journal, Aug. 1997, pp. 238-247, vol. 134, No. 2, Pt. 1, Mosby-Year Book, Inc.
De Ponti, F., et al., “QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience”,Eur J Clin Pharmacol, 2000, pp. 1-18, vol. 56, Springer-Verlag.
Dershwitz, M., et al. “Pharmacokinetics and Pharmacodynamics of Remifentanil in Volunteer Subjects with Severe Liver Disease”,Anesthesiology, Apr. 1996, pp. 812-820, vol. 84, No. 4, American Society of Anesthesiologists, Inc., Lippincott-Raven Publishers.
Kostrubsky, V., et al., “The Role of Conjugation in Hepatotoxicity of Troglitazone in Human and Porcine Hepatocyte Cultures”,Drug Metabolism and Disposition, 2000, pp. 1192-1197, vol. 28, No. 10, The American Society for Pharmacology and Experimental Therapeutics.
Rutledge et al. “The Binding Interactions of Ro 40-5967 at the L-type Ca2+ Channel in Cardiac Tissue”European Journal of Pharmacology, 1995, pp. 155-158, vol. 280.
Selnick, H., et al., “Class-III Antiarrhythmic Activity in Vivo By Selective Blockade of the Slowly Activating Cardiac Delayed Rectifier Potassium Current /Ksby (R)-2-(2,4-Triflouromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl] acetamide,”J. Med. Chem., Nov. 1997, pp. 3865-3868, vol. 40, No. 24, American Chemical Society.
Vandenberg, J., et al., “HERG K+ channels: friend and foe”,Trends in Pharmacological Sciences, May 2001, pp. 240-246, vol. 22, No. 5, Elsevier Science, Ltd.
Druzgala Pascal
Milner Peter G.
Pfister Jürg
Zhang Xiaoming
ARYx Therapeutics
Kantamneni Shobha
McDonnell Boehnen & Hulbert & Berghoff LLP
Padmanabhan Sreeni
LandOfFree
Materials and methods for the treatment of hypertension and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Materials and methods for the treatment of hypertension and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods for the treatment of hypertension and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3721826